Abstract:To examine the effects of cilostazol, a novel selective phosphodiesterase type 3 inhibitor, on soluble cell adhesion molecules (sCAMs) released from tumor necrosis factor-α (TNF-α)-stimulated human umbilical endothelial cells (HUVECs), and to investigate the possible mechanisms of these effects of cilostazol. METHODS: Confluent HUVECs between 4-6 passages were used and stimulated by TNF-α (10 μg*L-1) with or without coincubation of cilostazol (1-10 μmol*L-1) for 24 h. Soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble endothelial leukocyte adhesion molecule-1 (sELAM-1, sE-selectin) in cell culture medium were measured by ELISA, and availability of cells was detected by MTT assay. RESULTS: Cilostazol (1-10 μmol*L-1) did not affect sICAM-1 and sE-selectin released from HUVECs, but in contrast, it significantly inhibited the production of TNF-α-induced sVCAM-1, and this effect was canceled by Lω-nitro-L-arginine methyl ester (Lω-NAME, 0.1 μmol*L-1), a nonselective nitro oxide synthase (NOS) inhibitor. MTT assay indicated that the treatment of HUVECs with cilostazol (1-30 μmol*L-1) for 24 h affected cell availability in a complex pattern. It was increased at a low dose of cilostazol (1 μmol*L-1), but it was decreased at a relatively high dosage, 30 μmol*L-1. And at the medium dosage of cilostazol, 10 μmol*L-1, cell availability was almost unaffected. CONCLUSIONS: Cilostazol significantly inhibits sVCAM-1 released from TNF-α-activated HUVECs, and the effect on cytokine-challenged endothelial cells might have some relationship with activating NOS, and possibly, it is via a NO-dependent pathway. The present result suggests that cilostazol partially eliminates some of the adherent reactions of HUVECs to TNF-α, a deleterious cytokine, and to some extent, it might have the potential to prevent atherosclerosis and other cardiovascular diseases.

Cilostazol Regulates the Expressions of Endothelin-1 and Endothelial Nitric Oxide Synthase Via Activation of the P38 MAPK Signaling Pathway in HUVECs.

Effects of Cilostazol on Thrombospondin-1 (TSP-1) Expression Changes in the Myocardium of Diabetic Rats.

Effects of a phosphodiesterase 3 inhibitor, cilostazol on soluble adhesion molecules release from TNF-α-stimulated human umbilical endothelial cells

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

The Renal Protective Effects of Cilostazol on Suppressing Pathogenic Thrombospondin-1 and Transforming Growth Factor-β Expression in Streptozotocin-Induced Diabetic Rats

Cilostazol Suppresses Angiotensin Ii-Induced Apoptosis in Endothelial Cells

Effects of Diltiazem on Platelet Activation and Cytosolic Calcium During Percutaneous Transluminal Coronary Angioplasty.

Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease

Effects of cilostazol on LPS-stimulated adhesion and soluble adherent molecules release

Cilostazol Inhibits the Expression of Hnrnp A2/B1 and Cytokines in Human Dermal Microvascular Endothelial Cells.

The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression

Cilostazol Protects Diabetic Rats from Vascular Inflammation Via Nuclear Factor-κB-Dependent Down-Regulation of Vascular Cell Adhesion Molecule-1 Expression

Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis.

The Effect of Cilostazol on Expression of Thrombospondin-1 in Diabetic Retinopathy.

Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells

The anti-platelet drug cilostazol enhances heart rate and interrenal steroidogenesis and exerts a scant effect on innate immune responses in zebrafish

Effects of Ciloistazol VCAM-1NF-KB and PPARs in Aorta of STZ-induced Diabetes

Transcriptomic analysis reveals Cilostazol's role in ameliorating cardiovascular disease: Inhibition of monocyte-to-macrophage differentiation and reduction of endothelial cell reactive oxygen species production

Cilostazol Suppresses IL-23 Production in Human Dendritic Cells via an AMPK-Dependent Pathway

Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice

Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells.